Sage Therapeutics has been on a roll with good news lately.
This opinion piece presents the opinions of the author. It does not necessarily reflect the views of BioSpace.
SAGE Therapeutics didn’t waste any time. They announced positive top-line phase 3 results for their post-partum depression treatment brexanolone, along with intentions to file for approval in 2018. Then they did what any self-respecting biotech in their position would do: raise money. And lots of it. The company will gross $345 million from its recent public placement.
Meanwhile, Arcus Biosciences continues to attract lots of venture dollars, including another infusion from Google Ventures. The company just emerged from stealth mode last year with a focus on cancer I/O, and is now moving its first two programs into the clinic. Money is flowing elsewhere, too--read below for more key financing news from the past month. -KT
Here’s a roundup of these stories and other top financial news from the past month.
- Bay Area’s Arcus Biosciences Scores $107M, Initiates Two Clinical Trials
- Sage Therapeutics Announces Closing of $345M Public Offering of Common Stock
- 3D Medicines Raises $101M for Cancer Diagnostics and Drugs
- Founded by Genzyme Alumni, Cambridge’s X4 Pharma Scores $27M
- Johns Hopkins Gets a $65M Boost to Take Promising Drugs Into Clinic
Read More From Karl Thiel:
Are We Reaching the Biotech Singularity?
